news aktuell GmbH

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

29.11.2024 11:30:00 CET | news aktuell GmbH | Press Release

Share
  • Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
  • Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Oren Weininger CEO Copyright Strides Pharma International AG
Oren Weininger CEO Copyright Strides Pharma International AG

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.


Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.


The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.


Oren Weininger
, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”


Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.


For further information, please visit: www.fair-med.com/newsroom

                                                                   
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690


Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.


Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.

Images

Oren Weininger CEO Copyright Strides Pharma International AG
Oren Weininger CEO Copyright Strides Pharma International AG
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Ship parades, evening shows and partner region Liverpool The 837th HAMBURG PORT ANNIVERSARY with a top programme11.3.2026 13:11:09 CET | Press Release

Hamburg, 11 March 2026 – From 8 to 10 May 2026, Hamburg is celebrating its 837th HAMBURG PORT ANNIVERSARY. The programme includes traditional highlights such as the arrival and departure parades and the unique tugboat ballet, as well as several evening shows and the fascinating fireworks display. The programme will be supplemented by new events on the water and on land. The Big Arrival Parade on Friday, 8 May, at 1:30 p.m. marks the start of the festivities and is always an unforgettable experience: more than 100 impressive ships sail up the Elbe right before the eyes of the spectators. The majestic tall ship, the Norwegian three-masted barque Statsraad Lehmkuhl, is particularly stunning. The floating Elbe stage in front of the Landungsbrücken is THE artistic anchor of the HAMBURG PORT ANNIVERSARY: Elbe in Concert presents visitors with rousing live music and impressive performances, creating a unique atmosphere against the backdrop of the harbour skyline at night. This year’s partner

fiskaltrust Launches Portugal’s only Certified Fiscalisation Middleware and CashBox10.3.2026 08:30:00 CET | Press Release

Integration Partners and Commercial Partners can now access the Portuguese market through fiskaltrust's POS System API, covering full AT (Autoridade Tributária e Aduaneira) compliance. SALZBURG. fiskaltrust.eu, the European fintech company delivering Compliance-as-a-Service for point-of-sale systems, announced the launch of the only fully certified fiscalisation Middleware and CashBox for Portugal. Through a single integration to fiskaltrust's POS System API, Integration Partners can now access the Portuguese market with full compliance coverage without building or maintaining any local fiscal infrastructure themselves. fiskaltrust's certified Middleware and CashBox for Portugal handles the full compliance stack through the POS System API, the same interface used by Integration Partners across Austria, Germany, France, Italy, Spain, and Greece. Payments Integration Through Viva.com Every payment generates a fiscal event and fiskaltrust aligns payment and receipt data in real time. For

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:40:44 CET | Press Release

Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain. Under the agreement, BCWP will be responsible for obtaining marketing authorisation for Qutenza® in South Korea. Upon approval, the company will market and distribute the product. Grünenthal will receive an upfront payment in addition to regulatory and sales-related milestone payments. “We are executing on a dedicated strategy to bring Qutenza® into the Asia-Pacific region to facilitate greater access to non-opioid treatment opt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye